Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | AKR1B1 | P15121 | 6/20 | 0.38 |
| ▸ | CMA1 | P23946 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 5/20 | 0.34 |
| ▸ | CTSG | P08311 | 1/20 | 0.32 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23915005 | 0.90 | NPC1 (0.36) | SMN1; SMN2CMA1NPC1 | |
| SCHEMBL23915456 | 0.86 | AKR1B1 (0.38) | SMN1; SMN2AKR1B1CMA1SLC22A12MAPT | |
| SCHEMBL23915531 | 0.86 | NPC1 (0.35) | CMA1NPC1 | |
| SCHEMBL23914644 | 0.84 | NPC1 (0.33) | CMA1NPC1 | |
| SCHEMBL23908911 | 0.84 | MAPT (0.45) | AKR1B1NPC1MAPTS1PR2 | |
| SCHEMBL23915024 | 0.76 | CMA1 (0.32) | SMN1; SMN2CMA1 | |
| SCHEMBL23915533 | 0.76 | AKR1B1 (0.39) | AKR1B1NPC1MAPTPTGDR2 | |
| SCHEMBL23909037 | 0.73 | NPC1 (0.44) | SMN1; SMN2NPC1MAPTS1PR2 | |
| SCHEMBL31198904 | 0.73 | NPC1 (0.32) | NPC1 | |
| SCHEMBL23915532 | 0.72 | CMA1 (0.32) | CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | GILEAD SCIENCES, INC. | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210315893-A1 | NOVEL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF FIBROSIS | S1PR1, S1PR3, S1PR2 | SMN1; SMN2 2920/4885AKR1B1 124/4885CMA1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.